Welcome to the trials list!

Some tips to help get started:

  • Click on any trial title to view details, including trial sites, eligibility criteria, and our research about study drugs
  • If the list is long, use the search box and filters on the left to narrow down trials
  • Bookmark trials of interest by clicking the bookmark icon to the right of the trial title
Sign up to save your data! Arrow
Processing... Processing...

Clinical Trials for Other Solid Tumor

Search

Close
[Clear]

Filters

Location:
[Clear]
[Clear]

There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.

397 trials meet filter criteria.

Sort by:

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Teligene US (industry) Phase: 2 Start date: Dec. 27, 2023

HealthScout AI summary: This trial targets patients aged 18-75 with locally advanced or metastatic NSCLC featuring uncommon EGFR mutations, excluding those previously treated with EGFR-TKIs, and tests Sutetinib maleate, an irreversible EGFR tyrosine kinase inhibitor, for its efficacy and safety.

ClinicalTrials.gov ID: NCT06010329

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Regeneron Pharmaceuticals (industry) Phase: 2/3 Start date: June 30, 2023

HealthScout AI summary: This trial evaluates the efficacy and safety of fianlimab, an anti-LAG-3 antibody, combined with cemiplimab, an anti-PD-1 antibody, compared to cemiplimab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1 ≥50% who have not received prior systemic treatment.

ClinicalTrials.gov ID: NCT05785767

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Teligene US (industry) Phase: 2 Start date: Sept. 1, 2022

HealthScout AI summary: This trial is evaluating the efficacy and safety of Sutetinib Maleate Capsule, an investigational irreversible EGFR tyrosine kinase inhibitor, in adult patients with locally advanced or metastatic NSCLC harboring non-resistant uncommon EGFR mutations (L861Q, G719X, and/or S768I), who have had no more than one prior line of chemotherapy.

ClinicalTrials.gov ID: NCT05168566

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Merck Sharp & Dohme LLC (industry) Phase: 3 Start date: June 10, 2024

HealthScout AI summary: This trial targets adult patients with metastatic squamous non-small cell lung cancer and evaluates the efficacy of pembrolizumab combined with carboplatin and paclitaxel/nab-paclitaxel followed by pembrolizumab with or without the antibody-drug conjugate sacituzumab tirumotecan, which targets TROP2, in improving overall survival.

ClinicalTrials.gov ID: NCT06422143

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: AstraZeneca (industry) Phase: 3 Start date: Oct. 4, 2024

HealthScout AI summary: This trial targets patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer who have progressed after osimertinib treatment, evaluating the efficacy of Dato-DXd, an antibody-drug conjugate targeting TROP2, with or without osimertinib, against standard platinum-based doublet chemotherapy.

ClinicalTrials.gov ID: NCT06417814

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Eikon Therapeutics (industry) Phase: 2 Start date: Feb. 6, 2024

HealthScout AI summary: This trial examines EIK1001, a toll-like receptor 7/8 dual agonist, combined with pembrolizumab and chemotherapy, in adults with stage 4 non-small cell lung cancer who haven't received prior systemic treatment and lack actionable tumor mutations.

ClinicalTrials.gov ID: NCT06246110

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: OncoC4, Inc. (industry) Phase: 3 Start date: June 28, 2023

HealthScout AI summary: This trial involves adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after anti-PD-1/PD-L1 therapy and platinum-based chemotherapy, comparing the investigational anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) with docetaxel to evaluate their impact on overall survival.

ClinicalTrials.gov ID: NCT05671510

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: AstraZeneca (industry) Phase: 3 Start date: Nov. 18, 2024

HealthScout AI summary: The trial is evaluating the efficacy of rilvegostomig, a bispecific antibody targeting PD-1 and TIGIT, versus pembrolizumab, combined with platinum-based chemotherapy as a first-line treatment for patients with stage IV metastatic squamous non-small cell lung cancer expressing PD-L1 ≥ 1%, excluding those with actionable driver oncogenes.

ClinicalTrials.gov ID: NCT06692738

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Eli Lilly and Company (industry) Phase: 3 Start date: Dec. 21, 2023

HealthScout AI summary: The trial targets untreated patients with KRAS G12C-mutant, locally advanced or metastatic NSCLC, comparing the efficacy and safety of LY3537982, a KRAS G12C inhibitor, with pembrolizumab, with or without pemetrexed and platinum, against placebo and pembrolizumab regimens. Eligibility varies by PD-L1 expression level: ≥50% for Part A or any level for Part B.

ClinicalTrials.gov ID: NCT06119581

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: AstraZeneca (industry) Phase: 3 Start date: Aug. 3, 2022

HealthScout AI summary: This trial investigates the efficacy of savolitinib, a MET inhibitor, in combination with osimertinib compared to platinum-based chemotherapy in adult patients with EGFR-mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed following osimertinib therapy.

ClinicalTrials.gov ID: NCT05261399

First Previous Page 2 of 40 Next Last
Please help us improve by giving us feedback or feature requests. Email [email protected]
Copy email address
Email copied to clipboard